These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27716499)

  • 1. Empowering Older Antibiotics.
    Wright GD
    Cell; 2016 Oct; 167(2):301. PubMed ID: 27716499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
    Alidjanov JF; Fritzenwanker M; Hoffman I; Wagenlehner FM
    Future Microbiol; 2017 Jun; 12():655-670. PubMed ID: 28338347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA; Vinluan CM; Antony N
    Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
    Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
    [No Abstract]   [Full Text] [Related]  

  • 6. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A β-lactamase inhibitor revival provides new hope for old antibiotics.
    Garber K
    Nat Rev Drug Discov; 2015 Jul; 14(7):445-7. PubMed ID: 26129790
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.
    Asli A; Brouillette E; Krause KM; Nichols WW; Malouin F
    Antimicrob Agents Chemother; 2016 Feb; 60(2):752-6. PubMed ID: 26574008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
    Gardiner BJ; Golan Y
    Expert Rev Anti Infect Ther; 2016; 14(5):451-63. PubMed ID: 27042762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 12. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
    King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avibactam and inhibitor-resistant SHV β-lactamases.
    Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
    Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
    Durand-Réville TF; Guler S; Comita-Prevoir J; Chen B; Bifulco N; Huynh H; Lahiri S; Shapiro AB; McLeod SM; Carter NM; Moussa SH; Velez-Vega C; Olivier NB; McLaughlin R; Gao N; Thresher J; Palmer T; Andrews B; Giacobbe RA; Newman JV; Ehmann DE; de Jonge B; O'Donnell J; Mueller JP; Tommasi RA; Miller AA
    Nat Microbiol; 2017 Jun; 2():17104. PubMed ID: 28665414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
    Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
    J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
    Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
    J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
    Durand-Réville TF; Comita-Prevoir J; Zhang J; Wu X; May-Dracka TL; Romero JAC; Wu F; Chen A; Shapiro AB; Carter NM; McLeod SM; Giacobbe RA; Verheijen JC; Lahiri SD; Sacco MD; Chen Y; O'Donnell JP; Miller AA; Mueller JP; Tommasi RA
    J Med Chem; 2020 Nov; 63(21):12511-12525. PubMed ID: 32658473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.